Emily Blumberg, MD
Infectious Disease · Philadelphia, PANPI 1043247935
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,790 of the $16,930 with a category attached, or 87.4%. Biotest AG accounts for 64.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $10,890 and has fallen 81.3% since, to $2,040 in 2024. Among infectious disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $2418.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotest AG$11K
- E.r. Squibb & Sons, L.L.C.$3K
- Kamada Ltd.$2K
- Shionogi Inc$1K
Across 260 payments — averaging $2205.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$285K
- Scynexis, Inc.$117K
- Takeda Pharmaceuticals U.S.A., Inc.$82K
- Shire North American Group Inc$74K
- Modernatx, Inc.$10K
- Regeneron$5K
What the payments were for
- Consulting fees$14,79087%
- Speaking & faculty fees$2,04012%
- Food & beverage$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotest AG | 1 | $10,890 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,700 |
| Kamada Ltd. | 1 | $2,040 |
| Shionogi Inc | 2 | $1,300 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,930 in reported general payments places this provider in the 90th percentile of 457 infectious disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 45 | $183,279 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $110,002 |
| TivicayDolutegravir Sodium | 34 | $83,055 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $72,392 |
| JulucaDolutegravir/Rilpivirine | 18 | $63,101 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $36,374 |
| IsentressRaltegravir Potassium | 15 | $31,015 |
| Darunavir | 12 | $6,998 |
| Ritonavir | 12 | $885 |
| ValacyclovirValacyclovir Hcl | 19 | $735 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $267 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Philadelphia
- David HornPhiladelphia$2.1M
- Judith WolfPhiladelphia$1.2M
- Karam MounzerPhiladelphia$712K
- William ShortPhiladelphia$520K
- Pablo TebasPhiladelphia$160K
- Lisa SpacekPhiladelphia$131K
- Ian FrankPhiladelphia$112K
- Jay KostmanPhiladelphia$77K
- Ramon GadeaPhiladelphia$55K
- Vincent LorePhiladelphia$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.